Hypertension and hyperparathyroidism are associated with left ventricular hypertrophy in patients on hemodialysis

Indian Journal of Nephrology

Volumn 19, Issue 4, 2009, Pages 153-157

  Al Hilali, N ^a   Hussain, N ^a   Ataia, A ^a   Al Azmi, M ^a   Al Helal, B ^a   Johny, K ^a  

^a MUBARAK AL KABEER HOSPITAL   (Kuwait)

Author keywords

Hemodialysis; Hyperparathyroidism; Hypertension; Left ventricular hypertrophy

Indexed keywords

ADULT; ARTICLE; BODY SURFACE; CLINICAL EVALUATION; CONTROLLED STUDY; DIALYSIS; DISEASE ASSOCIATION; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERPARATHYROIDISM; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PARATHYROID GLAND; TREATMENT DURATION;

EID: 77953381970     PISSN: 09714065     EISSN: 19983662     Source Type: Journal    
DOI: 10.4103/0971-4065.59337     Document Type: Article

References (34)

1. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995;47:186-192
2. Amann K, Ritz E, Amann K. Cardiac disease in chronic uremia: Pathophysiology. Adv Ren Replace Ther 1997;4:212-224
3. Randon RB, Rohde LE, Comerlato L, Ribeiro JP, Manfro RC. The role of secondary hyperparathyroidism in left ventricular hypertrophy of patients under chronic hemodialysis. Braz J Med Biol Res 2005;38:1409-1416
4. Massry SG, Smogorzewski M. The heart in uremia. Seminars in Nephrology 1996;16:214-221
5. London GM, De Vernejoul MC, Fabiani F, Marchais SJ, Guerin AP, Metivier F, et al. Secondary hyperparathyroidism and cardiac hypertrophy in hemodialysis patients. Kidney Int 1987; 32:900-907
6. Avram MM, Sreedhara R, Avram DK, Muchnick RA, Fein P. Enrollment parathyroid hormone level is a new marker of survival in hemodialysis and peritoneal dialysis therapy for uremia. American Journal of Kidney Diseases 1996;28:924-930
7. Strózecki P, Adamowicz A, Nartowicz E, Odrowaz-Sypniewska G, Włodarczyk Z, Manitius J. Parathormone, calcium, phosphorus and left ventricular structure and function in normotensive hemodialysis patients. Renal Failure 2001;23:115-126
8. Kutlay S, Dincer I, Sengul S, Nergizoglu G, Duman N, Erturk S. The long-term behavior and predictors of left ventricular hypertrophy in hemodialysis patients. Am J Kidney Dis 2006;47:485-492
9. Harnett JD, Kent GM, Barre PE, Taylor R, Parfrey PS. Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. J Am Soc Nephrol 1994;4:1486-1490
10. Kawada H, Sumimoto T, Okayama H, Hiwada K. Structure and function of the left ventricle and carotid artery in hemodialysis patients. Hypertens Res 2001;24:221-227
11. Nishikimi T, Minami J, Tamano K, Takahashi M, Numabe A, Futoo Y. Left ventricular mass relates to average systolic blood pressure, but not loss of circadian blood pressure in stable hemodialysis patients: An ambulatory 48-hour blood pressure study. Hypertens Res 2001;24:507-514
12. Kannel WB. Left ventricular hypertrophy as a risk factor in arterial hypertension. Eur Heart J 1992;13: S82-S88
13. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 1996;49:1379-1385
14. Cuspidi C, Lonati L, Sampieri L, Macca G, Michev I, Salerno M, et al. Impact of blood pressure control on prevalence of left ventricular hypertrophy in treated hypertensive patients. Cardiology 2000;93:149-154 (Pubitemid 30759254)
15. London GM. Left ventricular alterations and end-stage renal disease. Nephrol Dial Transplant 2002;17:29-36.
16. NKF-DOQI clinical practice guidelines for hemodialysis adequacy. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis 1997;30: S15-66.
17. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man: Anatomic validation of the method. Circulation 1997;55:613-619
18. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol 1986;57:450-458
19. DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Int Med 1916;17:863-871
20. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;31:1561-1566
21. Spiegel DM, Raggi P, Mehta R, Lindberg JS, Chonchol M, Ehrlich J, et al. Coronary and aortic calcifications in patients new to dialysis. Hemodial Int 2004;8:265-272
22. Haydar AA, Covic A, Colhoun H, Rubens M, Goldsmith DJ. Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients. Kidney Int 2004;65:1790-1794
23. Nitta K, Akiba T, Uchida K, Otsubo S, Otsubo Y, Takei T, et al. Left ventricular hypertrophy is associated with arterial stiffness and vascular calcification in hemodialysis patients. Hypertens Res 2004;27:47-52.
24. Amann K, Ritz E, Wiest G, Klaus G, Mall G. A role of parathyroid hormone for activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 1994;4:1814-1819
25. Fujii H, Kim JI, Abe T, Umezu M, Fukagawa M. Relationship between parathyroid hormone and cardiac abnormalities in chronic dialysis patients. Intern Med 2007;46:1507-1512
26. Park CW, Oh YS, Shin YS, Kim CM, Kim YS, Kim SY, et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1999;33:73-81.
27. Harnett JD, Kent GM, Barre PE, Taylor R, Parfrey PS. Risk factors for thedevelopment of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. J Am Soc Nephrol 1994;4:1486-1490
28. Sobotová D, Zharfbin A, Svojanovsḱ J, Nedbá lková M. Hypertension in hemodialyzed uremic patients. Vnitr Lek 1999;45:641-644
29. Fliser D, Franek E, Fode P, Stefanski A, Schmitt CP, Lyons M, et al. Subacute infusion of physiological doses of parathyroid hormone raises blood pressure in humans. Nephrol Dial Transplant 1997;12:933-938
30. Randon RB, Rohde LE, Comerlato L, Ribeiro JP, Manfro RC. The role of secondary hyperparathyroidism in left ventricular hypertrophy of patients under chronic hemodialysis. Braz J Med Biol Res 2005;38:1409-1416
31. Kim HW, Park CW, Shin YS, Kim YS, Shin SJ, Kim YS, et al. Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis. Nephron Clinical Practice 2006;102:21-29
32. Chertow GM, Burke SK, Dillon MA, Slatopolsky E. Long-term effects of sevelamer hydrochloride on the calcium x phosphorus product and lipid profile of hemodialysis patients. Nephrol Dial Transplant 1999;14:2907-2914
33. Behets GJ, Verberckmoes SC, D'Haese PC, De Broe ME. Lanthanum carbonate: A new phosphorus binder. Curr Opin Nephrol Hypertens 2004;13:403-409
34. Block GA, Martin KJ, De Francisco AL, Turner SA, Avram MM, Suranyi MG, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. NEJM 2004;350:1516-1525